Aries Wealth Management Buys 76 Shares of IDEXX Laboratories, Inc. $IDXX

Aries Wealth Management lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,172 shares of the company’s stock after purchasing an additional 76 shares during the quarter. Aries Wealth Management’s holdings in IDEXX Laboratories were worth $1,701,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sagespring Wealth Partners LLC raised its stake in shares of IDEXX Laboratories by 38.7% during the 2nd quarter. Sagespring Wealth Partners LLC now owns 756 shares of the company’s stock valued at $406,000 after purchasing an additional 211 shares during the period. Equitable Trust Co. raised its stake in shares of IDEXX Laboratories by 28.1% during the 2nd quarter. Equitable Trust Co. now owns 2,368 shares of the company’s stock valued at $1,270,000 after purchasing an additional 519 shares during the period. TD Asset Management Inc raised its stake in shares of IDEXX Laboratories by 12.2% during the 2nd quarter. TD Asset Management Inc now owns 329,511 shares of the company’s stock valued at $176,730,000 after purchasing an additional 35,798 shares during the period. Wilmington Savings Fund Society FSB raised its stake in shares of IDEXX Laboratories by 9.5% during the 2nd quarter. Wilmington Savings Fund Society FSB now owns 2,071 shares of the company’s stock valued at $1,111,000 after purchasing an additional 179 shares during the period. Finally, RFG Advisory LLC raised its stake in shares of IDEXX Laboratories by 5.7% during the 2nd quarter. RFG Advisory LLC now owns 6,776 shares of the company’s stock valued at $3,634,000 after purchasing an additional 366 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a “buy” rating and a $625.00 price objective on the stock. Piper Sandler reiterated a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Leerink Partners boosted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. UBS Group started coverage on IDEXX Laboratories in a research report on Wednesday, October 1st. They set a “neutral” rating and a $720.00 target price for the company. Finally, BTIG Research boosted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $656.50.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 7,143 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president directly owned 18,007 shares in the company, valued at approximately $11,352,153.01. This represents a 28.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sharon E. Underberg sold 5,450 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the sale, the executive vice president owned 6,156 shares of the company’s stock, valued at $4,011,249.60. This represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 54,057 shares of company stock worth $34,293,468. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $636.91 on Wednesday. The business has a 50-day simple moving average of $640.40 and a 200 day simple moving average of $545.72. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The stock has a market cap of $50.96 billion, a price-to-earnings ratio of 53.03, a PEG ratio of 4.10 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the business earned $2.44 EPS. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.